

Bibliographie Christine DANEL

Essai **ANRS 12136 Temprano** , Essai randomisé évaluant l'intérêt des traitements antirétroviraux précoces et une prévention de la Tuberculose par INH chez des patients infectés par le VIH, à Abidjan, Côte d'Ivoire - Investigateur Coordinateur de 2008 à 2014

Articles princeps :

- **Danel C**, Moh R, Gabillard D, et Temprano study group ANRS 12136. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, **N Eng J Med**, 2015, July, 20 DOI: 10.1056/NEJMoa1507198
- Badje A, Moh R, Gabillard D, et al, for the Temprano ANRS 12136 Study Group Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. **Lancet Glob Health**. 2017 Nov; 5
- Eholié SP, Badje A, Kouame GM, N'takpe JB, Moh R, **Danel C**, Anglaret X. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. **AIDS Res Ther**. 2016 Jul 26;13:27.
- Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, Becker JE, Uhler L, Danel C, Messou E, Eholié S, Freedberg KA. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. *Antivir Ther*. 2013;18:45-55

Valorisation associée (modélisation, effets indésirables)

- Ouattara EN, MacLean RL, **Danel C**, Borre ED, Gabillard D, Huang M, Moh R, Paltiel AD, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. **PLoS One**. 2019 Jun 27;14
- Ouattara EN, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, **Danel C**, Paltiel AD, Eholié SP, Freedberg KA, Anglaret X. Clinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa: A Model-Based Analysis in Côte d'Ivoire. **J Acquir Immune Defic Syndr**. 2014 Jul 1;66 :294-302
- Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R, Carrou JL, Bohoussou F, Eholie SP, Anglaret X. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. *J Int AIDS Soc*. 2013 ; 30;16

Etudes associées à Temprano ANRS 12136

ANRS 12 224 Quantiferon Temprano - Investigateur Principal

- **Danel C**, Kabran M, Inwoley A, Badje A, Herrmann JL, Moh R, Lecarrou J, Gabillard D, Ntakpe JB, Deschamps N, Ouattara E, Perronne C, Eholie S, Anglaret X. Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa. *PLoS One*. 2014 Oct 16;9:e107245.

ANRS 12 253 Temprano résistance - Investigateur Principal

- Affi R, Gabillard D, Kouame GM, Ntakpe JB, Moh R, Badje A, **Danel C**, Inwoley A, Eholié SP, Anglaret X, Weiss L. Plasma sVCAM-1, antiretroviral therapy and mortality in HIV-1-infected West African adults. **HIV Med.** 2022 Aug;23:717-726.
- N'takpé JB, Gabillard D, Moh R, Gardiennet E, Toni TD, Kouame GM, Badje A, Emieme A, Karcher S, Le Carrou J, Ménan H, **Danel C**, Eholie SP, Rouzioux C, Anglaret X, Lambotte O Elite and viremic HIV-1 controllers in West Africa. **AIDS.** 2022 Jan 1;36:29-38.
- Gabillard D, N'Takpé JB, Chaix ML, Kouame GM, Moh R, Toni TD, Le Carrou J, Karcher S, Badje A, Emieme A, Menan H, **Danel C**, Anglaret X, Eholié SP; Temprano ANRS 12136 study group. Virological failure and drug resistance in West African HIV-infected adults who started ART immediately or deferred ART initiation. **J Antimicrob Chemother.** 2021 Sep 15;76 :2666-2674.
- Moh DR, Ntakpé JB, Gabillard D, Yayo-Emieme AA, Badjé A, Kouame GM, d'Aquin TT, **Danel C**, Anglaret X, Eholié SP. Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults. **BMC Infect Dis.** 2022 Jan 29;22:100.

ANRS 12 239 Temprano Social - Investigateur associée

- Kouamé G, **Danel C**, Moh R, Badjé A, Jean K, N'takpe JB, Gabillard D, Le Carrou J, du Loû AD, Deschamps N, Eholie S, Anglaret X. WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit? **AIDS.** 2014 Jun 19;28 :1533-5
- Jean K, Gabillard D, Moh R, **Danel C**, Desgrées-du-Loû A, N'takpe JB, Le Carrou J, Badjé A, Eholié S, Lert F, Anglaret X, Dray-Spira R. Decrease in sexual risk behaviours after early initiation of antiretroviral therapy: a 24-month prospective study in Côte d'Ivoire. **J Int AIDS Soc.** 2014 Jun 30;17:18977.
- Jean K, Gabillard D, Moh R, Danel C, Fassassi R, Desgrées-du-Loû A, Eholié S, Lert F, Anglaret X, Dray-Spira R. Effect of Early Antiretroviral Therapy on Sexual Behaviors and HIV-1 Transmission Risk Among Adults With Diverse Heterosexual Partnership Statuses in Cote d'Ivoire. **J Infect Dis** 2014; 1;209:431-40

ANRS 12 240 Hépatitis B : VarBva - Investigateur associée

- Kouamé GM, Gabillard D, Moh R, Badje A, Ntakpé JB, Emième A, Maylin S, Toni TD, Ménan H, Zoulim F, **Danel C**, Anglaret X, Eholié S, Lacombe K, Boyd A. Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4⁺ cell counts. **Antivir Ther.** 2021 Jan-Feb; 26 :25-33
- Mohareb AM, Kouamé GM, Gabassi A, Gabillard D, Moh R, Badje A, Emième A, Maylin S, Ménan H, Hyle EP, Delaugerre C, Danel C, Anglaret X, Lacombe K, Eholié SP, Boyd A Mortality in relation to hepatitis B virus (HBV) infection status among HIV-HBV co-infected patients in sub-Saharan Africa after immediate initiation of antiretroviral therapy. **J Viral Hepat.** 2021 Apr;28:621-629.
- Boyd A, Maylin S, Moh R, Mahjoub N, Gabillard D, Eholié SP, Danel C, Anglaret X, Zoulim F, Girard PM, Delaugerre C, Lacombe K; ANRS 12240 VarBVA study Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfecting patients from Sub-Saharan Africa. **J Gastroenterol Hepatol.** 2016 Mar;31(3):634-44

- Kouamé GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, Ntakpe JB, Emième A, Maylin S, Chekaraou MA, Eholié SP, Zoulim F, Lacombe K, Anglaret X, Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. **Clin Infect Dis**. 2018 Jan 6;66(1):112-120.
- Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, **Danel C**, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa. **Liver Int**. 2019 Feb;39:280-289.

Preco CI ANRS 12277 Cohorte de séroconvertisseurs en Côte d'Ivoire - Investigateur Principal

- Minga A, Danel C, Abo Y, Dohoun L, Bonard D, Coulibaly A, Duvignac J, Dabis F, Salamon R, Anglaret X; ANRS 1220 Study Group. Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire. *Bull World Health Organ*. 2007 ;85:116-23.
- Toni T, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, Chenal H, Dabis F, Salamon R, Fleury HJ; Primo-CI ANRS 1220 Study Group. HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006. *AIDS Res Hum Retroviruses*. 2007;23:1155-60.
- Abo Y, Minga A, Menan H, Danel C, Ouassa T, Dohoun L, Bomisso G, Tanoh A, Messou E, Eholié S, Lewden C, Anglaret X, Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008 *BMC Infectious Diseases*. 2013, 13:607
- Minga A, Lewden C, Dohoun L, Abo Y, Emieme A, Coulibaly A, Salamon R, Eholie S, Anglaret X, Danel C. Short Communication: Severe Symptomatic Hyperlactatemia Among HIV Type 1-Infected Adults on Antiretroviral Therapy in Cote d'Ivoire. *AIDS Res Hum Retroviruses*, 2010;26, 991-5.
- Ekouevi DK, Coffie PA, Ouattara E, Moh R, Amani-Bosse C, Messou E, Sissoko M, Anglaret X, Eholié SP, Danel C, Dabis F. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the leDEA West Africa and ANRS databases, Abidjan, Côte d'Ivoire for the International epidemiological Database to Evaluate AIDS (leDEA) West Africa, ANRS 1269 and ANRS 12136 study groups in Abidjan. *J Acquir Immune Defic Syndr*. 2011; 56:183-7.

ANRS12 287 and 12323 DOD-CI Offres et Demandes de Dépistage HIV and Hepatitis B and C Testing : social study. Investigateur associée

- Inghels M, Kouassi AK, Niangoran S, Bekelync A, Carillon S, Sika L, **Danel C**, Kone M, du Loû AD, Larmarange J; ANRS 12323 DOD-CI Study Group. Cascade of Provider-Initiated Human Immunodeficiency Virus Testing and Counselling at Specific Life Events (Pregnancy, Sexually Transmitted Infections, Marriage) in Côte d'Ivoire. **Sex Transm Dis**. 2020 Jan;47:54-61

ANRS 12 237 Fozivudine in Africa Phase II trial. Investigateur Associée

- Arne Kroidl¹, Frederic Ello, Jimson Mgaya, Tessa Lennemann, Raoul Moh, Lucas Maganga, Serge Eholie, Alain Pruvost, Elmar Saathoff, Pierre-Marie Girard, Ralph Zuhse, Friedrich von Massow, Xavier Anglaret, Michael Hoelscher, Christine Danel; FATI-1 study team, **Virological efficacy of 24-week fozivudine-based regimen in ART-naïve patients from Tanzania and Côte d'Ivoire**, *AIDS* 2017 Feb 20;31(4):501-509. doi: 10.1097/QAD.0000000000001362.

ANRS 12 269 Statis, Investigatrice Pays

- Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, Samreth S, Nguyen BD, Borand L, Domergue A, Rapoud D, Natukunda N, Thai S, Juchet S, Eholié SP, Lawn SD, Domoua SK, Anglaret X, Laureillard D; STATIS ANRS 12290 Trial Team. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults. **N Engl J Med**. 2020 Jun 18; 382 :2397-2410.

ANRS 12294 FIT 2. Etude pilote de phase 2 évaluant la tolérance et l'efficacité de 3 stratégies de traitements ARV pour des patients infectés par le VIH 2, en Afrique Sub Saharienne - membre du DSMB

- Serge P Eholie¹, Didier K Ekouevi², Corine Chazallon³, Charlotte Charpentier⁴, Eugène Messou⁵, Zelica Diallo¹, Jacques Zoungrana⁶, Albert Minga⁷, Ndeye Fatou Ngom Gueye⁸, Denise Hawerlander⁹, Fassery Dembele¹⁰, Géraldine Colin³, (...) Xavier Anglaret¹⁷, Françoise Brun-Vezinet⁴; FIT-2 study group Efficacy and safety of three antiretroviral therapy regimens for treatment-naïve African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial, **Lancet HIV** 2024 Jun;11(6):e380-e388. doi: 10.1016/S2352-3018(24)00085-7. Epub 2024 May 10.

ANRS 12361 PREP-CI, Etude de faisabilité en vue d'un essai clinique sur une prophylaxie préexposition (PrEP) orale à la demande chez des femmes exposées au VIH en Côte d'Ivoire - Investigateur associée

- Becquet V, Nouaman M, Plazy M, Masumbuko JM, Anoma C, Kouame S, **Danel C**, Eholie SP, Larmarange J; ANRS 12361 PrEP-CI Study group. Sexual health needs of female sex workers in Côte d'Ivoire: a mixed-methods study to prepare the future implementation of pre-exposure prophylaxis (PrEP) for HIV prevention. **BMJ Open**. 2020 Jan 8;10

ANRS 12311 TAC Faisabilité, tolérance, et Efficacité d'un traitement par Sofosbuvir chez des patients porteurs d'une hépatite C en Côte d'Ivoire- investigatrice associée

- Lacombe K, Moh R, Chazallon C, Lemoine M, Sylla B, Fadiga F, Le Carrou J, Marcellin F, Kouanfack C, Ciaffi L, Sartre MT, Sida MB, Diallo A, Gozlan J, Seydi M, Cissé V, Danel C, Girard PM, Toni TD, Minga A, Boyer S, Carrieri P, Attia A; Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC **ANRS 12311** trial). TAC ANRS12311 Study Group.Sci Rep. 2024 May 3;14(1):10244. doi: 10.1038/s41598-024-57013-1.

JKI trial, Essai de phase II évaluant l'efficacité et la tolérance du Favipravir chez les patients atteint de Maladie à Virus Ebola, Guinée 2014

- Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, ...See abstract for full author list → Experimental Treatment with Favipiravir for Ebola Virus Disease (the **JKI Trial**): A Historically Controlled, Single-Arm Proof-of-Concept **Trial** in Guinea.PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967.

Essai ANRS 1269 Trivacan-Essai thérapeutique multicentrique randomisé pour évaluer des stratégies d'interruption thérapeutiques programmées de traitements antirétroviraux chez des adultes infectés par le VIH, à Abidjan en Côte d'Ivoire, Investigateur Coordinateur de 2002 à 2007

Publications princeps

- **Danel C**, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, Nzunetu, G.Gabillard, D.Rouet, F.Sorho, S.Chaix, M. L.Eholie, S.Menan, H.Sauvageot, D.Bissagnene, E.Salamon, R.Anglaret, X. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. **Lancet**. 2006;367;1981-9.
- **Danel C**, Moh R, Chaix ML, Gabillard D, Gnokoro J, Diby CJ,Toni, T.Dohoun, L.Rouzioux, C.Bissagnene, E.Salamon, R.Anglaret, X.. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. **J Infect Dis**. 2009 ;199:66-76.

Consequences ITP

- Ndri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni TA, Chenal H, Seyler C, Gabillard D,. Wakasugi N, Eholie S, **Danel C**. Occult hepatitis B virus infection in untreated HIV-infected adults in Côte d'Ivoire. **Antivir Ther**. 2010;15 :1029-34.
- Pasquet A, Messou E, Gabillard D, Minga A, Depoulosky A, Deuffic-burban S, Losina E, Freedberg KA, **Danel C**, Anglaret X, and Yazdanpanah Y. Impact of antiretroviral drug stock-outs on death and interruption in care among HIV-infected patients in three HIV care centres in Abidjan, Côte d'Ivoire, **Plos one**,2010 ;15:e13414.
- Protopopescu C, Marcellin F, Préau M, Gabillard D, Moh R, Minga A, Anzian A, Carrieri MP, **Danel C**, Spire B. Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269) **Trop Med Int Health**. 2010;15 :706-12.

Effets des traitements: efficacité et effets indésirables

- Moh R, **Danel C**, Messou E, Ouassa T, Gabillard D, Anzian A, Abo, Y. Salamon, R. Bissagnene, E. Seyler, C. Eholie, S. Anglaret, X. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. **AIDS**. 2007 ;21:2483-91.
- Messou E, Gabillard D, Moh R, Inwoley A, Sorho S, Eholié S, Rouet F, Seyler C, **Danel C**, Anglaret X. Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults. **Bull World Health Organ**. 2008 ;86:435-42.
- Messou E, Chaix M L, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, **Danel C**, Sloan C E, Rouzioux C, Freedberg K A, and Anglaret X. Association between medication possession ratio, virologic failure and drug resistance in HIV-1 infected adults on antiretroviral therapy in Côte d'Ivoire. **J Acquir Immune Defic Syndr**, 2011; 56:356-64.
- **Danel C**, Gabillard D, Inwoley A, Chaix ML, Toni TD, Moh R, Messou E, Bissagnene E, Salamon R, Eholie S, Anglaret X.Medium-term probability of success of antiretroviral treatment after early warning signs of treatment failure in West African adults. **AIDS Res Hum Retroviruses**. 2009;25:783-93.

- Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, **Danel C**, Sloan C, Rouzioux C, Freedberg KA, Anglaret X. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. **J Acquir Immune Defic Syndr**. 2011;56,356-64.
- **Danel C**, Moh R, Anzian A, Abo Y, Chenal H, Guehi C, Gabillard D, Sorho S, Rouet, F. Eholie, S. Anglaret, X. et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. **J Acquir Immune Defic Syndr**. 2006 ;42:29-35.
- Moh R, **Danel C**, Sorho S, Sauvageot D, Anzian A, Minga A, Ba Gomis O, Kanga C, Eholié S, Inwoley A, Gabillard D, Bissagnene E, Salamon R, Anglaret X. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire, **Antivir Ther**, 2005,10: 615-24
- **Danel C**, Moh R, Peytavin G, Anzian A, Minga A, Ba Gomis O, Seri B, Nzunettu G, Gabillard D, Salamon R, Bissagnene E, Anglaret X. Lack of indinavir-associated nephrological complications in predominantly HIV-1 infected women with high indinavir plasma concentration in Abidjan, Côte d'Ivoire. **AIDS Res and Hum retroviruses** 2006; 23: 62-66
- Marcellin F, Moh R, Carrieri MP, **Danel C**, Protopopescu C, Gabillard D, Spire B, Anglaret X. Depressive symptoms and exposure to efavirenz in West African HIV-infected adults. **HIV Clin Trials**. 2008;9:445-7.

Modélisations

- Yazdanpanah Y, Wolf LL, Anglaret X, Gabillard D, Walensky RP, Moh R, **Danel C**, Sloan CE, Losina E, Freedberg KA. CD4-guided structured treatment interruptions of antiretroviral therapy in HIV disease: Projecting beyond clinical trials. **Antivir Ther**, 2010;15:351-61.
- Kimmel AD, Resch SC, Anglaret X, Daniels N, Goldie SJ, Danel C, Wong AY, Freedberg KA, Weinstein MC. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. **Cost Eff Resour Alloc**. 2012, 19;10:12